Literature DB >> 16827600

Desirable therapeutic characteristics of an optimal antihypertensive agent.

Lisa Mustone Alexander1.   

Abstract

Hypertension affects 65 million people in the US, and is a major cause of morbidity and mortality, but less than one-third of patients with hypertension are treated to goal blood pressure. Multiple factors have been cited, and include suboptimal adherence to treatment and lifestyle modifications, limited access to healthcare services, and the failure of health professionals to treat hypertension aggressively. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7) recommends a goal blood pressure of <140/90mm Hg for most patients and <130/80mm Hg for those with diabetes mellitus or chronic kidney disease. The 'ideal' antihypertensive agent would have a number of characteristics: (i) effective in lowering blood pressure to recommended goals; (ii) high efficacy as monotherapy; (iii) rapid onset of effect; (iv) convenient once-daily dose administration to maximise compliance; (v) sustained efficacy over 24 hours; (vi) response increases with higher doses (clear dose-response effect); and (vii) optimum tolerability profile. Although the ideal agent does not yet exist and will vary from patient to patient, drug development and new formulations have provided more options for clinicians and patients and certain drug classes appear to show promise because they possess many beneficial characteristics. Hypertension treatment needs to be tailored to individual patients' age, race, socioeconomic situation, concomitant conditions and family history. Physicians and other clinical providers have an important role to play in hypertension management, particularly by combining culturally sensitive patient care with aggressive treatment. Regular follow-up that is directed at achieving goal blood pressure, while monitoring the patient for possible drug-related adverse effects, will help ensure and support adherence to treatment regimens. By supporting the integration of lifestyle changes into this plan, the clinician can further influence and have a positive impact on a patient's overall cardiovascular profile.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16827600     DOI: 10.2165/00003495-200666090-00006

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  70 in total

1.  Discontinuation of antihypertensive drugs due to adverse events: a systematic review and meta-analysis.

Authors:  S D Ross; K S Akhras; S Zhang; M Rozinsky; L Nalysnyk
Journal:  Pharmacotherapy       Date:  2001-08       Impact factor: 4.705

2.  Characteristics of patients with uncontrolled hypertension in the United States.

Authors:  D J Hyman; V N Pavlik
Journal:  N Engl J Med       Date:  2001-08-16       Impact factor: 91.245

3.  Effects of a structured treatment algorithm on blood pressure goal rates in both stage 1 and stage 2 hypertension.

Authors:  J M Neutel; D H G Smith; T N Silfani; Y Lee; M A Weber
Journal:  J Hum Hypertens       Date:  2006-04       Impact factor: 3.012

4.  Incidence and characteristics of angioedema associated with enalapril.

Authors:  John B Kostis; Harold J Kim; James Rusnak; Thomas Casale; Allen Kaplan; Jonathan Corren; Elliott Levy
Journal:  Arch Intern Med       Date:  2005-07-25

Review 5.  Tolerability, safety, and quality of life and hypertensive therapy: the case for low-dose diuretics.

Authors:  M R Weir; J M Flack; W B Applegate
Journal:  Am J Med       Date:  1996-09-30       Impact factor: 4.965

Review 6.  Comparative safety and tolerability of angiotensin II receptor antagonists.

Authors:  L Mazzolai; M Burnier
Journal:  Drug Saf       Date:  1999-07       Impact factor: 5.606

Review 7.  Cough and angioneurotic edema associated with angiotensin-converting enzyme inhibitor therapy. A review of the literature and pathophysiology.

Authors:  Z H Israili; W D Hall
Journal:  Ann Intern Med       Date:  1992-08-01       Impact factor: 25.391

8.  Use of 24-hour ambulatory blood pressure monitoring to assess antihypertensive efficacy: a comparison of olmesartan medoxomil, losartan potassium, valsartan, and irbesartan.

Authors:  David H G Smith; Robert Dubiel; Michael Jones
Journal:  Am J Cardiovasc Drugs       Date:  2005       Impact factor: 3.571

9.  Patterns of hypertension management in Italy: results of a pharmacoepidemiological survey on antihypertensive therapy. Scientific Committee of the Italian Pharmacoepidemiological Survey on Antihypertensive Therapy.

Authors:  E Ambrosioni; G Leonetti; A C Pessina; A Rappelli; B Trimarco; A Zanchetti
Journal:  J Hypertens       Date:  2000-11       Impact factor: 4.844

Review 10.  New European, American and International guidelines for hypertension management: agreement and disagreement.

Authors:  George S Stergiou; Eleanna V Salgami
Journal:  Expert Rev Cardiovasc Ther       Date:  2004-05
View more
  4 in total

Review 1.  Differential Metabolic Effects of Beta-Blockers: an Updated Systematic Review of Nebivolol.

Authors:  Maria Marketou; Yashaswi Gupta; Shashank Jain; Panos Vardas
Journal:  Curr Hypertens Rep       Date:  2017-03       Impact factor: 5.369

Review 2.  Aliskiren: a review of its use in the management of hypertension.

Authors:  James E Frampton; Monique P Curran
Journal:  Drugs       Date:  2007       Impact factor: 9.546

Review 3.  Torasemide prolonged release.

Authors:  Katherine A Lyseng-Williamson
Journal:  Drugs       Date:  2009-07-09       Impact factor: 9.546

4.  Clinical utility of fixed-combination telmisartan-amlodipine in the treatment of hypertension.

Authors:  Julian Segura; Luis M Ruilope
Journal:  Integr Blood Press Control       Date:  2011-05-19
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.